Skip to content

The effect of Local production of red clover on Knee Osteoarthritis

The effect of local production of red clover on the clinical criteria of Knee Osteoarthritis in elderly

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016121131355N1
Enrollment
80
Registered
2017-02-15
Start date
2017-01-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. Primary gonarthrosis

Interventions

Intervention 1: intervention Group: local production red clover twice a day, each time 10 drops (containing 40 mg isoflavones) and routine treatment with meloxicam tablets. Intervention 2: Control: ol
Treatment - Drugs
intervention Group: local production red clover twice a day, each time 10 drops (containing 40 mg isoflavones) and routine treatment with meloxicam tablets
Control: olive oil 10 drops twice a day and routine treatment with meloxicam tablet

Sponsors

Research and Technology Vice-Chancellory of Mashhad University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for this study include the following: Initial symptomatic osteoarthritis in at least one knee by clinical or radiological criteria ACR (American College of Rheumatology) is approved; a score higher than 40 at baseline VAS scale; Obtain routine medical treatment (meloxicam tablets) for at least two weeks before the study; aged between 60 and 80 years Exclusion criteria are as follows: The patient dissatisfaction cooperation during the study; The need for new therapeutic intervention during the study period; skin disease or ulcer at the site of drug; effects (local or systemic probable) by treatments performed during the study; active liver disease or renal malignancies; Secondary osteoarthritis or suspected; patients treated with hormonal drugs; anticoagulation therapy; Patients with a history of ischemic or hemorrhagic stroke; patients with a history of deep vein thrombosis; The 4-week treatment with oral corticosteroids at baseline; The intra-articular injection of hyaluronic acid in the three months before the start of the study; BMI> 37kg / m2; clinically obvious swelling of the knee joint disease (stroke test> trace)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Early intervention, two weeks after the intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Womac questionnaire and vas scale.;Joint stiffness. Timepoint: Early intervention, two weeks after the intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Womac questionnaire.;Physical performance. Timepoint: Early intervention, two weeks after the intervention, four weeks after the intervention, eight weeks after intervention. Method of measurement: Womac questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoud Mokhtari

Faculty of Iranian Traditional Medicine and Complementary of Mashhad University of Medical Sciences

mokhtarim921@mums.ac.irmokhtarimasud@gmail.com+98 51 3876 5591

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026